Soleno Therapeutics Inc. [NASDAQ: SLNO] price surged by 13.04 percent to reach at $0.24. On June 29, 2020, the clinical-stage biopharmaceutical company made an announcement of its addition to the Russell 3000® Index. This new addition to Russell indexes happened after the annual reconstitution.
The Chief Executive Officer of Soleno Therapeutics, Anish Bhatnagar said that they are gratified with the addition to the Russell 3000® Index. He further added that with the advancement in their current program of Diazoxide Choline Controlled-Release tablets for Prader-Willi Syndrome patients, this addition will help the investors to see a better side of the company and magnify the liquidity of firms shares.
A sum of 2546476 shares traded at recent session while its average daily volume was at 744.29K shares. Soleno Therapeutics Inc. shares reached a high of $2.09 and dropped to a low of $1.86 until finishing in the latest session at $2.08.
The average equity rating for SLNO stock is currently 1.50, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Soleno Therapeutics Inc. [SLNO]:
Craig Hallum have made an estimate for Soleno Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 10, 2020. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on December 23, 2019, representing the official price target for Soleno Therapeutics Inc. stock. Previously, the target price had yet another drop from $8 to $4, while Maxim Group kept a Buy rating on SLNO stock.
The Average True Range (ATR) for Soleno Therapeutics Inc. is set at 0.30 The Price to Book ratio for the last quarter was 9.90.
SLNO Stock Performance Analysis:
Soleno Therapeutics Inc. [SLNO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.47. With this latest performance, SLNO shares dropped by -38.10% in over the last four-week period, additionally sinking by -22.39% over the last 6 months – not to mention a drop of -25.71% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SLNO stock in for the last two-week period is set at 40.94, with the RSI for the last a single of trading hit 44.33, and the three-weeks RSI is set at 40.82 for Soleno Therapeutics Inc. [SLNO]. The present Moving Average for the last 50 days of trading for this stock 2.93, while it was recorded at 1.90 for the last single week of trading, and 2.43 for the last 200 days.
Insight into Soleno Therapeutics Inc. Fundamentals:
Return on Total Capital for SLNO is now -101.60, given the latest momentum, and Return on Invested Capital for the company is -135.69. Return on Equity for this stock declined to -135.69, with Return on Assets sitting at -75.68. When it comes to the capital structure of this company, Soleno Therapeutics Inc. [SLNO] has a Total Debt to Total Equity ratio set at 2.04. Additionally, SLNO Total Debt to Total Capital is recorded at 2.00, with Total Debt to Total Assets ending up at 0.80.
Reflecting on the efficiency of the workforce at the company, Soleno Therapeutics Inc. [SLNO] managed to generate an average of -$1,230,960 per employee.Soleno Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 2.10.
SLNO Stock EPS
With the latest financial reports released by the company, Soleno Therapeutics Inc. posted -0.31/share EPS, while the average EPS was predicted by analysts to be reported at -0.17/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -82.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SLNO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Soleno Therapeutics Inc. go to 15.00%.
Soleno Therapeutics Inc. [SLNO] Insider Position Details
There are presently around $38 million, or 47.30% of SLNO stock, in the hands of institutional investors. The top three institutional holders of SLNO stocks are: ABINGWORTH LLP with ownership of 6,969,272, which is approximately 0% of the company’s market cap and around 1.30% of the total institutional ownership; NANTAHALA CAPITAL MANAGEMENT, LLC, holding 4,277,923 shares of the stock with an approximate value of $7.87 million in SLNO stocks shares; and ORACLE INVESTMENT MANAGEMENT INC, currently with $7.12 million in SLNO stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Soleno Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 20 institutional holders increased their position in Soleno Therapeutics Inc. [NASDAQ:SLNO] by around 1,462,109 shares. Additionally, 7 investors decreased positions by around 597,147 shares, while 7 investors held positions by with 18,703,746 shares. The mentioned changes placed institutional holdings at 20,763,002 shares, according to the latest SEC report filing. SLNO stock had 12 new institutional investments in for a total of 842,228 shares, while 1 institutional investors sold positions of 35,500 shares during the same period.